Calcium antagonists such as diltiazem may play a promising role in reducing ischaemia during percutaneous transluminal coronary angioplasty (PTCA) and in preventing cardiac events in patients with unstable angina. An ongoing study, the Incomplete INfarction Trial of European Research Collaborators Evaluating Prognosis post-Thrombolysis/Tildiem® (INTERCEPT), also aims to investigate whether prophylactic administration of diltiazem and aspirin can reduce the incidence of ischaemic complications in patients with a first acute myocardial infarction (MI) who are receiving thrombolytic therapy. These and other data were presented at a satellite symposium sponsored by Synthélabo, which was held at the XVIIth Congress of the European Society of Cardiology [Amsterdam, The Netherlands; August 1995].